Revlimid vs Skyrizi
Side-by-side drug price comparison from Medicare Part D data
Verdict
Skyrizi costs 65% less per claim than Revlimid ($4475.00 vs $12786.00). Neither drug has a generic alternative available. Total Medicare spending: Revlimid at $7.8B vs Skyrizi at $2.3B.
| Metric | Revlimid | Skyrizi |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $12,786 | $4,475* |
| Total Medicare Spending Total Medicare Part D spending on this drug | $7.8B | $2.3B |
| Total Claims | 612,000 | 524,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | -3.4%* | 42.8% |
| Generic Available | No | No |
| Condition | Cancer | Autoimmune Diseases |
| Total Beneficiaries | 58,000 | 78,000 |
Skyrizi costs 65% less per claim than Revlimid ($4475.00 vs $12786.00). Neither drug has a generic alternative available. Total Medicare spending: Revlimid at $7.8B vs Skyrizi at $2.3B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both entity A and entity B. What follows is the interpretation — which specific axes carry the most weight for entity A versus entity B, and which differences are large enough to influence a real decision.
Practical use of the comparison: read the data above, then drill into the individual entity A and entity B detail pages for the underlying breakdown. A pairwise comparison answers the relative question; the per-entity pages answer the absolute question.
Source: CMS Medicare Part D Spending, 2026.